DiscoverHealthTech Deep DiveOpenEvidence, the ChatGPT for doctors, raises $200 million at $6 billion valuation. How does it differ from general LLMs and UpToDate, and why is it gaining traction among healthcare professionals?
OpenEvidence, the ChatGPT for doctors, raises $200 million at $6 billion valuation. How does it differ from general LLMs and UpToDate, and why is it gaining traction among healthcare professionals?

OpenEvidence, the ChatGPT for doctors, raises $200 million at $6 billion valuation. How does it differ from general LLMs and UpToDate, and why is it gaining traction among healthcare professionals?

Update: 2025-10-27
Share

Description

This podcast episode provides a multi-faceted overview of advancements in medical technology and healthcare digitization, with a strong focus on artificial intelligence. A significant portion of the text discusses OpenEvidence, a medical-specific AI platform often called "ChatGPT for doctors," detailing its rapid valuation growth, free usage for U.S. healthcare professionals, and its competitive advantage through formal partnerships with journals like NEJM and JAMA to access paywalled content. Additionally, the text highlights innovations in medical robotics and smart sanitation, specifically mentioning a Chinese startup's automated blood collection robot and new toilet-integrated devices from Kohler and TOTO designed to analyze excrement for health monitoring. These diverse examples illustrate the increasing application of advanced technology to alleviate healthcare burdens and enhance diagnostics.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

OpenEvidence, the ChatGPT for doctors, raises $200 million at $6 billion valuation. How does it differ from general LLMs and UpToDate, and why is it gaining traction among healthcare professionals?

OpenEvidence, the ChatGPT for doctors, raises $200 million at $6 billion valuation. How does it differ from general LLMs and UpToDate, and why is it gaining traction among healthcare professionals?

Kazutaka Yoshinaga